In fiscal 2026, which ended Jun 30, 2026, Phibro Animal Health Corporation reported revenue of $1.5 billion, up 17.1% from the year before. Net income was $99.7 million, a profit margin of 6.6%. Operating income came to $194.4 million, an operating margin of 12.8%. Diluted earnings per share were $2.43. Over the twelve months ended Sep 30, 2026, revenue was $1.5 billion and net income was $102.7 million. Across the 10 fiscal years shown, revenue grew from $764.3 million in fiscal 2017 to $1.5 billion in fiscal 2026, about 7.9% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2027
Sep 30, 2026
|
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
FY 2017
Jun 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1,541
+10.1%
|
1,518
+17.1%
|
1,296
+27.4%
|
1,018
+4.1%
|
978
+3.8%
|
942
+13.1%
|
833
+4.1%
|
800
-3.3%
|
828
+1.0%
|
820
+7.3%
|
764
+1.7%
|
| Cost of revenue |
1,020
+5.8%
|
1,006
+12.2%
|
896
+27.2%
|
705
+3.7%
|
680
+3.5%
|
657
+16.9%
|
562
+3.4%
|
543
-3.5%
|
563
+1.9%
|
553
+7.2%
|
516
+0.7%
|
| Gross profit |
521
+19.5%
|
513
+28.1%
|
400
+27.7%
|
313
+5.0%
|
298
+4.5%
|
285
+5.2%
|
271
+5.6%
|
257
-2.9%
|
265
-0.8%
|
267
+7.5%
|
248
+3.9%
|
| Research and development |
—
|
25
+3.5%
|
24
-18.7%
|
29
+19.7%
|
24
+17.1%
|
21
+17.3%
|
18
+29.3%
|
14
+13.6%
|
12
+21.0%
|
10
+5.9%
|
9
-14.4%
|
| Selling, general and administrative |
328
+12.4%
|
318
+9.9%
|
289
+11.4%
|
260
+14.7%
|
226
+9.7%
|
206
+5.0%
|
197
+4.7%
|
188
+3.5%
|
181
+8.0%
|
168
+11.7%
|
150
-1.9%
|
| Operating income |
193
+33.8%
|
194
+76.0%
|
110
+107.2%
|
53
-25.8%
|
72
-9.0%
|
79
+5.5%
|
75
+8.2%
|
69
-16.9%
|
83
-15.9%
|
99
+1.0%
|
98
+14.2%
|
| Pretax income |
140
+47.8%
|
137
+102.0%
|
68
+522.9%
|
11
-79.8%
|
54
-25.2%
|
72
+8.8%
|
66
+19.7%
|
56
-22.4%
|
72
-18.8%
|
88
+9.3%
|
81
+4.9%
|
| Income tax |
37
+38.5%
|
38
+90.7%
|
20
+132.1%
|
8
-60.4%
|
21
-7.3%
|
23
+91.6%
|
12
-45.0%
|
22
+30.8%
|
17
-27.6%
|
23
+45.6%
|
16
+366.9%
|
| Net income |
103
+51.5%
|
100
+106.6%
|
48
+1897.7%
|
2
-92.6%
|
33
-33.7%
|
49
-9.6%
|
54
+62.1%
|
34
-38.7%
|
55
-15.7%
|
65
+0.4%
|
65
-21.9%
|
| Basic EPS |
2.53
+51.3%
|
2.46
+106.7%
|
1.19
+1883.3%
|
0.06
-92.6%
|
0.81
-33.1%
|
1.21
-9.7%
|
1.34
+61.4%
|
0.83
-38.5%
|
1.35
-16.1%
|
1.61
-1.2%
|
1.63
-22.7%
|
| Diluted EPS |
2.51
+50.6%
|
2.43
+104.2%
|
1.19
+1883.3%
|
0.06
-92.6%
|
0.81
-33.1%
|
1.21
-9.7%
|
1.34
+61.4%
|
0.83
-38.5%
|
1.35
-16.1%
|
1.61
+0.0%
|
1.61
-22.2%
|
| Weighted average shares, basic |
41
+0.1%
|
41
+0.1%
|
41
+0.0%
|
41
+0.0%
|
41
+0.0%
|
41
+0.1%
|
40
+0.0%
|
40
+100003.9%
|
0
+0.6%
|
0
+1.7%
|
0
+0.7%
|
| Weighted average shares, diluted |
41
+0.6%
|
41
+0.7%
|
41
+0.4%
|
41
+0.0%
|
41
+0.0%
|
41
+0.0%
|
41
+0.0%
|
41
+99853.1%
|
0
+0.3%
|
0
+0.9%
|
0
+0.2%
|
| Other measures | |||||||||||
| Depreciation and amortization |
52
+5.7%
|
52
+13.0%
|
46
+26.1%
|
36
+6.4%
|
34
+4.0%
|
33
+2.6%
|
32
-1.4%
|
32
+17.3%
|
28
+2.3%
|
27
+3.6%
|
26
+10.9%
|
| EBITDA |
245
+26.7%
|
246
+57.6%
|
156
+74.4%
|
89
-15.5%
|
106
-5.2%
|
112
+4.6%
|
107
+5.1%
|
102
-8.4%
|
111
-12.0%
|
126
+1.6%
|
124
+13.5%
|
| Interest coverage |
4.18x
|
4.19x
|
2.97x
|
2.32x
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Margins | |||||||||||
| Gross margin |
33.83%
|
33.76%
|
30.85%
|
30.77%
|
30.50%
|
30.29%
|
32.56%
|
32.10%
|
31.96%
|
32.55%
|
32.48%
|
| Operating margin |
12.51%
|
12.81%
|
8.52%
|
5.24%
|
7.35%
|
8.38%
|
8.98%
|
8.65%
|
10.05%
|
12.06%
|
12.81%
|
| Pretax margin |
9.08%
|
9.05%
|
5.25%
|
1.07%
|
5.53%
|
7.68%
|
7.98%
|
6.94%
|
8.64%
|
10.74%
|
10.54%
|
| Profit margin |
6.67%
|
6.57%
|
3.72%
|
0.24%
|
3.33%
|
5.22%
|
6.53%
|
4.19%
|
6.61%
|
7.91%
|
8.45%
|
| EBITDA margin |
15.90%
|
16.20%
|
12.04%
|
8.79%
|
10.83%
|
11.85%
|
12.81%
|
12.69%
|
13.38%
|
15.35%
|
16.22%
|
| Effective tax rate |
26.56%
|
27.40%
|
29.02%
|
77.87%
|
39.70%
|
32.01%
|
18.18%
|
39.56%
|
23.48%
|
26.33%
|
19.78%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PAHC (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Teaneck, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1069899
- Former names
- PHILIPP BROTHERS CHEMICALS INC (until May 14, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.